ArticleCureus2026
Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to compare diabetic retinal disease onset or progression between established semaglutide or tirzepatide users and patients without documented exposure to either drug. Secondary exploratory objectives included medication-specific comparisons, adjusted analyses, and visual acuity assessment. Regional nonarteritic anterior ischemic optic neuropathy (NAION) case ascertainment was evaluated separately and descriptively.
methodsThis retrospective cohort reviewed retinal records covering January 1, 2025, through March 31, 2026. Of 342 patients screened, 221 were excluded, leaving 121 records with two bilateral retinal assessments approximately one year apart. Analysis was at the patient-record level. Thirty patients received the same study drug before baseline and throughout follow-up; 91 had no documented exposure to either drug. Incident diabetic retinopathy (DR) and/or diabetic macular edema (DME) was evaluated among records without baseline disease, and progression was evaluated separately among records with baseline disease. Risk ratios (RRs), 95% confidence intervals (CIs), exact tests, and exploratory adjusted models were calculated. A separate regional NAION search covered January 1, 2022, through December 31, 2025, followed by investigator review of identified cases and medication histories.
resultsThe combined retinal endpoint occurred in 12/30 exposed and 46/91 unexposed records (40.0% versus 50.5%; RR: 0.79, 95% CI: 0.49-1.28; p = 0.400). Incident disease occurred in 7/14 versus 32/43 records (RR: 0.67; 95% CI: 0.39-1.17), and progression occurred in 5/16 versus 14/48 records (RR: 1.07; 95% CI: 0.46-2.51). Combined event proportions differed across semaglutide, tirzepatide, and unexposed categories (2/14, 10/16, and 46/91; global p = 0.017). No NAION was recorded in the retinal cohort. None of the seven separately identified regional NAION cases had documented study-drug use after investigator review.
conclusionsNo statistically significant association was detected for the combined retinal endpoint, but estimates were imprecise. Medication-specific findings were exploratory and do not establish comparative safety. Regional NAION findings were descriptive and could not quantify or exclude an association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.